GB2348701B - Assays,methods and means - Google Patents

Assays,methods and means

Info

Publication number
GB2348701B
GB2348701B GB0006533A GB0006533A GB2348701B GB 2348701 B GB2348701 B GB 2348701B GB 0006533 A GB0006533 A GB 0006533A GB 0006533 A GB0006533 A GB 0006533A GB 2348701 B GB2348701 B GB 2348701B
Authority
GB
United Kingdom
Prior art keywords
assays
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0006533A
Other versions
GB2348701A (en
GB0006533D0 (en
Inventor
Stephen Philip Jackson
Daniel Durocher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kudos Pharmaceuticals Ltd
Original Assignee
Kudos Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906432.1A external-priority patent/GB9906432D0/en
Application filed by Kudos Pharmaceuticals Ltd filed Critical Kudos Pharmaceuticals Ltd
Publication of GB0006533D0 publication Critical patent/GB0006533D0/en
Publication of GB2348701A publication Critical patent/GB2348701A/en
Application granted granted Critical
Publication of GB2348701B publication Critical patent/GB2348701B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
GB0006533A 1999-03-19 2000-03-17 Assays,methods and means Expired - Fee Related GB2348701B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9906432.1A GB9906432D0 (en) 1999-03-19 1999-03-19 Assays,methods and means
GBGB9915075.7A GB9915075D0 (en) 1999-03-19 1999-06-28 Assays,methods and means

Publications (3)

Publication Number Publication Date
GB0006533D0 GB0006533D0 (en) 2000-05-10
GB2348701A GB2348701A (en) 2000-10-11
GB2348701B true GB2348701B (en) 2001-06-20

Family

ID=26315311

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0006533A Expired - Fee Related GB2348701B (en) 1999-03-19 2000-03-17 Assays,methods and means

Country Status (4)

Country Link
EP (1) EP1163521A2 (en)
AU (1) AU3440700A (en)
GB (1) GB2348701B (en)
WO (1) WO2000057184A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660511B1 (en) * 2000-03-03 2003-12-09 Rigel Pharmaceuticals, Inc. Methods of screening for modulation of cell cycle
US8008035B2 (en) 2007-01-25 2011-08-30 Roche Diagnostics Operations, Inc. Enhancement of vanadium-containing phosphatase inhibitors
EP1949894B1 (en) * 2007-01-25 2016-06-29 Roche Diagnostics GmbH Enhancement of vanadium-containing phosphatase inhibitors by polyols
US10370776B2 (en) * 2013-09-25 2019-08-06 Idea Orchard, Llc Antibody like protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763164A (en) * 1993-04-16 1998-06-09 Northwestern University Immunogenic cancer proteins and peptides and methods of use
GB9803399D0 (en) * 1998-02-19 1998-04-15 Imp Cancer Res Tech Protein kinase c

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J Mol. Biol. Vol. 294 1999. Liao H et.al. pages 1041-1049 *
Molecular Cell Vol. 4 1999. Durocher D et.al. pages 387-394 *
Science Vol. 281 1998. Sun Z et.al. pages 272-274 *
Trends in Biochem. Sci. Vol. 20 (9) 1995. Hofmann K & BucherP pages 347-349 *

Also Published As

Publication number Publication date
WO2000057184A3 (en) 2001-03-08
GB2348701A (en) 2000-10-11
GB0006533D0 (en) 2000-05-10
AU3440700A (en) 2000-10-09
WO2000057184A2 (en) 2000-09-28
EP1163521A2 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
MXPA01013362A (en) ANTI-alphav.
HK1052037A1 (en) Structural member.
EG24361A (en) 4-pyrimiding1-n-acy1.l.phenlalanines
GB9911569D0 (en) Antibodies
HK1053470A1 (en) 4-Pyridinyln-acyl-l-phenylalanines.
EP1210084A4 (en) Pyridomorphinans, thienomoprhinans and use thereof
GB0007933D0 (en) Assays,methods and means
GB9905817D0 (en) Methods
GB9926161D0 (en) Methods
GB9714971D0 (en) Assays,therapeutic methods and means
GB2348701B (en) Assays,methods and means
GB9904401D0 (en) Assay method
GB9921684D0 (en) Assays
GB9813778D0 (en) Assay methods and means
GB0010191D0 (en) Assays, methods and means
GB9928882D0 (en) Assay method
GB9913556D0 (en) Assays
GB9915075D0 (en) Assays,methods and means
GB0128964D0 (en) Assays, methods and means
GB0030059D0 (en) Polypeptides, methods and means
HK1031254A1 (en) Tachogragh.
GB9908525D0 (en) Methods
GB9914943D0 (en) Methods
GB0118952D0 (en) Assays,methods and means
GB0111574D0 (en) Assays,methods and means

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20100317